Chronic inflammation and your heart: the risk factor hiding in plain sight

Cardiovascular disease remains the leading cause of death in Switzerland. According to the Swiss Heart Foundation, roughly one in three deaths is attributable to heart disease or stroke. What most people picture when they think about heart attack risk is the classic checklist: high cholesterol, high blood pressure, smoking, lack of exercise, poor diet, family history. And those matter. But they don't explain everything.

About half of all heart attacks occur in people whose cholesterol levels would not have flagged them as high-risk. Over the past two decades, a growing body of evidence has pointed to chronic, low-grade inflammation as a potential driver of cardiovascular events, one that operates quietly alongside traditional risk factors and often goes entirely unmeasured, and therefore unaddressed.

The tricky part is that this kind of inflammation doesn't feel like the typical acute inflammatory response we feel after injury. There's no fever, no swelling, no pain. It's a slow biochemical process happening inside your blood vessel walls. Luckily, there are specific blood markers that indicate chronic inflammation.

What low-grade inflammation actually is

Inflammation is your immune system's response to injury or infection. When you cut your finger, the redness and warmth you see is acute inflammation doing its job: clearing debris, fighting pathogens, starting repair. It ramps up quickly and resolves once the threat is gone.

Low-grade chronic inflammation is different. It's a persistent, low-level activation of the immune system that doesn't resolve. Instead of responding to a single event, the body stays in a state of mild immune alertness for months or years. The triggers are varied: visceral fat (which is metabolically active and produces inflammatory signaling molecules), insulin resistance, poor sleep, chronic stress, smoking, a sedentary lifestyle, or an imbalanced diet high in processed foods.

This low-level inflammation doesn't produce obvious symptoms. You won't feel it the way you feel a sore throat. But inside your blood vessels, it's accelerating the process of atherosclerosis: the buildup of plaque in your arterial walls.

How inflammation drives cardiovascular disease

The connection between inflammation and heart disease isn't new, but it took decades to move from hypothesis to hard evidence. Here's the mechanism in simplified terms.

Atherosclerosis begins when LDL cholesterol particles penetrate the inner lining of an artery and become trapped in the vessel wall. The immune system recognizes these particles as foreign to their natural milieu and sends white blood cells (macrophages) to engulf them. Over time, these macrophages become bloated with cholesterol, forming so-called foam cells. This is the beginning of plaque.

Chronic inflammation makes this process worse at every stage. Inflammatory signaling molecules (cytokines like interleukin-6 and interleukin-1β) recruit more immune cells to the site, thicken the plaque, and destabilize it. A stable plaque can sit in an artery for years without causing harm. An inflamed, unstable plaque is the one that ruptures, triggering the blood clot that causes a heart attack or stroke.

This is why two people with identical cholesterol numbers can have very different outcomes. The person with higher inflammation has more unstable plaque and a greater likelihood that something will rupture.

The evidence: "SMuRF-less but inflamed"

In preventive cardiology, the standard modifiable risk factors have a name: SMuRFs (standard modifiable risk factors), meaning hypertension, dyslipidemia, diabetes, and smoking. If you don't have any of these, you're considered low-risk by most screening algorithms. But a substantial proportion of cardiovascular events still occurs in people with none of these factors, particularly in women.

A landmark study published in the European Heart Journal in 2026 by Paul Ridker and colleagues examined exactly this population. The researchers followed 12,530 initially healthy women from the NIH-funded Women's Health Study who had no standard modifiable risk factors, meaning their blood pressure, cholesterol, blood sugar, and smoking status were all unremarkable. The only thing measured at baseline that differed was hsCRP (high-sensitivity C-reactive protein), a blood marker of systemic inflammation.

The results over 30 years were striking. Women with hsCRP above 3 mg/L had a 77% higher risk of coronary heart disease events, a 39% higher risk of ischemic stroke, and a 52% higher risk of total cardiovascular events compared to those with hsCRP below 1 mg/L. CHD risk increased 21% for each increasing quintile of hsCRP. These women would have looked perfectly healthy by every standard metric. The only signal was inflammation.

The study's authors coined the term "SMuRF-less but inflamed" for these individuals, people who slip through conventional screening because they have no traditional risk factors, yet carry meaningful cardiovascular risk that shows up only when you measure inflammation.

These findings didn't come out of nowhere. Two earlier trials built the foundation.

The JUPITER trial (2008) enrolled 17,802 apparently healthy people with normal LDL cholesterol but elevated hsCRP. Rosuvastatin (a statin) reduced cardiovascular events by 38% in this group, lowering both LDL by 50% and hsCRP by 37%. JUPITER was the first major trial to show that targeting inflammation, not just cholesterol, could prevent heart attacks in otherwise healthy people.

The CANTOS trial (2017) went further. Ridker and colleagues tested canakinumab, a monoclonal antibody that blocks interleukin-1β (a key inflammatory cytokine), in 10,061 post-heart attack patients with persistently elevated hsCRP. Canakinumab reduced cardiovascular events without changing cholesterol levels at all. This was the definitive proof that inflammation itself, independent of cholesterol, drives cardiovascular risk.

Taken together, these three studies tell a clear story: chronic low-grade inflammation is a cardiovascular risk factor you can measure, and one you can act on. The challenge is that most screening programs still don't measure it.

The markers that matter

If low-grade inflammation is this important, the natural question is: how do you measure it? A few key markers:

• hsCRP (high-sensitivity C-reactive protein). This is the most validated inflammatory marker for cardiovascular risk assessment. CRP is produced by the liver in response to inflammatory signals (primarily IL-6). The "high-sensitivity" assay measures it at very low concentrations, which is what you need for cardiovascular risk stratification. The American College of Cardiology and the European Society of Cardiology both recognize hsCRP as a useful adjunct to traditional risk scores. Risk categories: below 1 mg/L is low, 1–3 mg/L is moderate, above 3 mg/L is high.
• ESR (erythrocyte sedimentation rate). A less specific but broadly useful marker of systemic inflammation. Elevated ESR alongside elevated hsCRP strengthens the signal.
• White blood cell differential. The composition of your white blood cells, particularly the neutrophil-to-lymphocyte ratio, can indicate chronic immune activation even when individual counts are within normal ranges.
• ApoB and lipid ratios. While not inflammatory markers per se, apolipoprotein B (the protein that carries LDL into artery walls) interacts directly with the inflammatory process. Knowing your ApoB alongside your hsCRP gives a more complete picture of your atherosclerotic risk than either alone.

Here's the catch: a standard Swiss Grundversicherung check-up typically includes a basic lipid panel (total cholesterol, HDL, LDL, triglycerides) and perhaps a fasting glucose. hsCRP is not part of routine screening in most GP practices. Neither is ApoB. This means the inflammatory component of your cardiovascular risk often goes entirely unmeasured. At Ahead Health, hsCRP, ApoB, and a full white blood cell differential are part of every advanced blood panel we run.

What you can do about elevated inflammation

The encouraging part: low-grade inflammation is modifiable. For many people, the same interventions that improve metabolic health also lower inflammation.

Visceral fat is one of the strongest drivers. Adipose tissue around the organs is metabolically active, producing IL-6 and other inflammatory cytokines. Reducing visceral fat through sustained dietary changes and regular physical activity has a direct anti-inflammatory effect. This doesn't require dramatic weight loss; even modest reductions in waist circumference are associated with measurable drops in hsCRP.

Diet matters specifically. A Mediterranean-style eating pattern, rich in vegetables, legumes, nuts, olive oil, and fatty fish, is consistently associated with lower hsCRP and lower cardiovascular event rates in European populations. The omega-3 fatty acids in fish (EPA and DHA) have direct anti-inflammatory properties.

Regular moderate exercise , around 150 minutes per week, reduces inflammatory markers independently of weight loss. Sleep quality is underrated: chronic short sleep (below 6 hours) is associated with elevated CRP. And smoking cessation has one of the largest single effects on reducing systemic inflammation.

For people with persistently elevated hsCRP despite lifestyle optimization, the conversation with a physician shifts toward pharmacological options. Statins reduce both LDL and hsCRP. Low-dose colchicine, an old anti-inflammatory drug, has shown cardiovascular benefit in recent trials. These are clinical decisions, not self-medication, but they start with knowing your numbers.

How Ahead Health fits in

At Ahead Health, we see inflammation markers regularly in our advanced blood panels. What we see often: people with textbook-normal cholesterol who have quietly elevated hsCRP. Without measuring it, there's no way to know.

The Ahead advanced blood test (CHF 299) includes 80+ biomarkers, covering hsCRP, ApoB, HbA1c, insulin, ESR, and a full white blood cell differential. These markers, taken together, give a much more complete cardiovascular risk profile than a standard lipid panel alone. Each result comes with a physician-reviewed report and a personalized action plan.

If your inflammatory markers are elevated, the next question is what's already happening in your arteries. A heart CT calcium score (CHF 470) measures calcified plaque in the coronary arteries directly. It takes minutes, uses a low dose of radiation, and gives you a number: a score of zero means no detectable calcified plaque, while higher scores indicate buildup that may warrant closer monitoring or intervention. Pairing hsCRP with a calcium score is one of the most informative combinations in preventive cardiology: the blood test tells you about the inflammatory process, the scan tells you about the structural result.

For ongoing tracking, the Ahead membership (from CHF 299/year) includes up to four blood tests per year, so you can see whether your inflammatory markers respond to the changes you're making. A single hsCRP reading is useful. A trend over 6 to 12 months is far more informative, because it tells you whether the underlying process is improving, stable, or getting worse.

Supplementary health insurers may cover part of the cost for our full-body check-ups. For example, KPT's supplementary insurance 'Pulse' reimburses up to CHF 1,500 for Ahead Health services.

Conclusion

Low-grade inflammation is not a fringe theory. It's an established, evidence-backed cardiovascular risk factor with decades of research behind it, including two landmark clinical trials that changed how cardiologists think about prevention. The limitation isn't the science; it's the gap between what we know and what gets routinely measured. Knowing your hsCRP alongside your lipids doesn't replace traditional risk assessment. It sharpens it, sometimes considerably. And unlike many risk factors, inflammation is something you can act on.